First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment: the RAAFT-3 Trial
Enrolling By Invitation
99 years and younger
All
10 participants needed
1 Location
Brief description of study
To determine if catheter-based atrial fibrillation (AF) ablation is superior to treatment with antiarrhythmic drugs as a first-line therapy for symptomatic persistent AF
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Atrial Fibrillation, afib
-
Age: - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 829475
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
